The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|September 23, 2015
Tailor-made solutions for the healthcare industry
Visit B. Braun OEM at ICSE 2015. Themed by “We are with you right from the start“ we will walk you through our service portfolio from offering products for your clinical trial to successful market launch of your product.
Advertisement
Visit B. Braun OEM at ICSE 2015. Themed by “We are with you right from the start“ we will walk you through our service portfolio from offering products for your clinical trial to successful market launch of your product.
B. Braun OEM Division. Tailor-made solutions for the healthcare industryExpertise in contract manufacturing and infusion therapy products
B. Braun supplies healthcare markets worldwide and is employing approx. 54,000 individuals.
The company is currently represented in more than 62 countries worldwide and the portfolio comprises more than 120,000 pharmaceutical and medical articles.
B. Braun OEM offers standard products or customized versions. Even the standard range contains hundreds of product versions, with which countless applications can be implemented.
Standard products
- Infusion and injection solutions
- Medical devices for drug admixture
- Automated infusion pumps
- Products for venipuncture and injection
- Products for infection prevention
OEM is specialized in developing customer-specific solutions for you. Most of our products can be individually adapted to your requirements.
Customized products and services
- Contract manufacturing
- Product development and private labeling
- Product combination
We look forward to meeting you at our booth 1D21!
B. Braun Melsungen AG
OEM Division Europe
Carl-Braun-Strasse 1
34212 Melsungen
Germany
Phone: +49 5661 71-0
Fax: +49 5661 71-3562
info-europe@bbraunoem.com
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement